KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Reply to Francesco Montorsi, Giuseppe Rosiello, Giorgio Gandaglia, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol 2023;6:508-15. PMID 37978025 · Eur Urol Oncol · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010. PMID 37951819 · Eur Urol Oncol · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy. PMID 37055663 · Prostate Cancer Prostatic Dis · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Interventional radiology meets immuno-oncology for hepatocellular carcinoma. PMID 35988688 · J Hepatol · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Methodology of clinical trials on sodium-glucose cotransporter 2 inhibitors registered on ClinicalTrials.gov: a cross-sectional study. PMID 39080564 · BMC Med Res Methodol · 2024-Jul-30 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Feasibility of a new 'balanced binocular viewing' treatment for unilateral amblyopia in children aged 3-8 years (BALANCE): results of a phase 2a randomised controlled feasibility trial. PMID 39079927 · BMJ Open · 2024-Jul-30 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
RecurIndex-Guided postoperative radiotherapy with or without Avoidance of Irradiation of regional Nodes in 1-3 node-positive breast cancer (RIGAIN): a study protocol for a multicentre, open-label, randomised controlled prospective, phase III trial. PMID 39079921 · BMJ Open · 2024-Jul-30 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effects of Immunotherapy on Quality-of-Life Outcomes in Patients with Gastroesophageal Cancers: A Meta-Analysis of Randomized Controlled Trials. PMID 39120199 · Healthcare (Basel) · 2024-Jul-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Author Correction: Oral micronized progesterone for perimenopausal night sweats and hot flushes a Phase III Canada-wide randomized placebo-controlled 4 month trial. PMID 39060366 · Sci Rep · 2024-Jul-27 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan. PMID 39123376 · Cancers (Basel) · 2024-Jul-25 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 4 Figure · 8 Panel · risk visible
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. PMID 38847460 · N Engl J Med · 2024-Jul-25 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Molecular Hydrogen for Outpatients with COVID-19 (Hydro-COVID): A Phase 3 Randomised, Triple-Blinded, Pragmatic, Placebo-Controlled, Multicentre Trial. PMID 39124575 · J Clin Med · 2024-Jul-24 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND. PMID 39053948 · RMD Open · 2024-Jul-24 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial. PMID 39043871 · Sci Rep · 2024-Jul-23 The record describes a secondary analysis of stem cell collection and hematological recovery from a Phase III randomized trial (FIL-MCL0208) that does involve a drug intervention (lenalidomide maintenance) and time-to-event endpoints (PFS, OS). However, the specific report is not the primary or definitive result report of the drug's efficacy; it is a focused secondary analysis on procedural factors and their impact, which falls under a secondary report type and is excluded per the criteria for original formal-result reports of primary/key secondary efficacy endpoints.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Beyond Standard Endocrine Therapy: A New Adjuvant Treatment in High-Risk Early Breast Cancer. PMID 39802529 · J Adv Pract Oncol · 2024-Jul-22 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Secondary Cytoreductive Surgery in Relapsed Platinum-Sensitive Epithelial Ovarian Cancer: A Systematic Review of Randomized Controlled Trials. PMID 39061251 · Cancers (Basel) · 2024-Jul-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial. PMID 39030637 · Trials · 2024-Jul-19 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Correction: PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial. PMID 39026293 · BMC Cancer · 2024-Jul-18 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Whole-body hypothermia in mild neonatal encephalopathy: protocol for a multicentre phase III randomised controlled trial. PMID 39026197 · BMC Pediatr · 2024-Jul-18 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Adjuvant immune checkpoint inhibitors for urothelial carcinoma: systematic review and Meta-analysis. PMID 39023778 · World J Urol · 2024-Jul-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Differential effects of desvenlafaxine on hot flashes in women with breast cancer taking tamoxifen: a randomized controlled trial. PMID 39019875 · NPJ Breast Cancer · 2024-Jul-17 The record describes a randomized Phase 3 trial with a drug intervention (desvenlafaxine) in oncology patients. However, the study's primary endpoint is the change rate in hot flash scores, a symptom/quality-of-life measure, not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the cohort's requirement for a primary/key secondary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An Approach to Improve Endometrial Receptivity: Is It Beneficial to Flush The Uterine Cavity with Follicular Fluid and Granulosa Cells? A Phase III Randomised Clinical Trial. PMID 39033367 · Int J Fertil Steril · 2024-Jul-13 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase III randomized clinical trial comparing laparoscopic radical hysterectomy based on open state with abdominal radical hysterectomy in patients with early-stage cervical cancer. PMID 38992720 · Trials · 2024-Jul-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D. PMID 38842520 · N Engl J Med · 2024-Jul-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial. PMID 38987693 · BMC Cancer · 2024-Jul-10 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials. PMID 38824414 · Oncologist · 2024-Jul-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Improving Quality of Life in Bipolar Disorders with an Immersive Virtual Reality Remediation Training Randomized Controlled Trial (RCT). PMID 38999451 · J Clin Med · 2024-Jul-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Completion Rate and Positive Results Reporting Among Immunotherapy Trials in Breast Cancer, 2004-2023. PMID 39028669 · JAMA Netw Open · 2024-Jul-01 This is a systematic review/meta-analysis of multiple trials, not an original formal report of a single randomized trial. It also does not focus on or report a specific time-to-event efficacy endpoint (OS, PFS, etc.) for a drug intervention.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Study protocol for ADAPT-TDM: A beta-lactam antibiotic Dose AdaPtation feasibility randomised controlled Trial using Therapeutic Drug Monitoring. PMID 38951004 · BMJ Open · 2024-Jul-01 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Assessing Direct and Spillover Effects of Intervention Packages in Network-randomized Studies. PMID 38709023 · Epidemiology · 2024-Jul-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tenecteplase Versus Alteplase in Acute Ischemic Stroke in Chinese Patients: Protocol for the ORIGINAL Study. PMID 41585404 · Stroke Vasc Interv Neurol · 2024-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis. PMID 39076530 · ERJ Open Res · 2024-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment. PMID 39070749 · Lancet Reg Health Eur · 2024-Jul The trial meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result, but lacks a time-to-event efficacy endpoint. The primary outcome is tumour size change (continuous), not OS, PFS, DFS, EFS, RFS, TTP, or any time-to-event measure.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics. PMID 39040578 · ERJ Open Res · 2024-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer. PMID 39032926 · J Gynecol Oncol · 2024-Jul 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Impact of PD-1/PD-L1 inhibitors on survival in stage III non-small-cell lung cancer: A systematic review. PMID 39027153 · Cancer Pathog Ther · 2024-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Development of a Web-Based Interactive Tool for Visualizing Breast Cancer Clinical Trial Tolerability Data. PMID 39013121 · JCO Clin Cancer Inform · 2024-Jul The record describes a study developing a visualization tool for tolerability data, using NSABP-B35 trial data as an example. It is not a primary report of time-to-event efficacy results for a drug intervention.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer. PMID 38993541 · Lancet Reg Health West Pac · 2024-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials. PMID 38932728 · Obesity (Silver Spring) · 2024-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023. PMID 38925083 · ESMO Open · 2024-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis. PMID 38922484 · Dermatol Ther (Heidelb) · 2024-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. PMID 38904749 · Dermatol Ther (Heidelb) · 2024-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study. PMID 38897136 · ESMO Open · 2024-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis. PMID 38896380 · Dermatol Ther (Heidelb) · 2024-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure. PMID 38888681 · Am J Clin Dermatol · 2024-Jul 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Tranexamic acid versus oxytocin prophylaxis in reducing post-partum blood loss, in low-risk pregnant women: TRANOXY STUDY, a phase III randomized clinical trial. PMID 38873634 · EClinicalMedicine · 2024-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study. PMID 38873632 · EClinicalMedicine · 2024-Jul The record is for a Phase II trial in vitiligo (non-oncology) with a continuous efficacy endpoint, not a time-to-event endpoint. It fails multiple core eligibility criteria.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study. PMID 38834087 · Lancet Oncol · 2024-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis. PMID 38824269 · Target Oncol · 2024-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19. PMID 38771550 · Infect Dis Ther · 2024-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -